Intestinal obstruction with Xifaxanta
Intestinal obstruction is now listed as an adverse reaction in the summary of product characteristics for Xifaxanta (rifaximin; Norgine). Additionally, the drug may reduce the effectiveness of oral estrogenic contraceptives if taken concomitantly. Caution should also be exercised when rifaximin is given concomitantly with a P-glycoprotein inhibitor, such as ciclosporin.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200182
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com